{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T21:09:58Z","timestamp":1771448998637,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"DOI":"10.7759\/cureus.103856","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T20:26:07Z","timestamp":1771446367000},"source":"Crossref","is-referenced-by-count":0,"title":["From Molecular Silence to Lymphoid Blast Phase: Diagnostic and Therapeutic Challenges in a Young Female Patient With Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Zainab H","family":"Alqallaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Atwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024, 99:2191-212. 10.1002\/ajh.27443","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman AE","year":"2021","unstructured":"Osman AE, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021, 49:10.1016\/j.blre.2021.100825","journal-title":"Blood Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131703","article-title":"Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights","volume":"12","author":"Iezza M","year":"2023","unstructured":"Iezza M, Cortesi S, Ottaviani E, et al.. Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights. Cells. 2023, 12:10.3390\/cells12131703","journal-title":"Cells"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.4826","article-title":"Complete cytogenetic response to nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: a case report","volume":"13","author":"Liu B","year":"2016","unstructured":"Liu B, Zhang W, Ma H. Complete cytogenetic response to nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: a case report. Mol Med Rep. 2016, 13:2635-8. 10.3892\/mmr.2016.4826","journal-title":"Mol Med Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti L","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M, et al.. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014, 93:71-80. 10.1007\/s00277-013-1937-4","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi EJ","year":"2023","unstructured":"Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023, 58:29-36. 10.5045\/br.2023.2023017","journal-title":"Blood Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023, 8:262. 10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004194","article-title":"Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs","volume":"5","author":"Er\u00e7al\u0131\u015fkan A","year":"2021","unstructured":"Er\u00e7al\u0131\u015fkan A, Seyhan Erdo\u011fan D, E\u015fkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv. 2021, 5:3344-53. 10.1182\/bloodadvances.2021004194","journal-title":"Blood Adv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911836","article-title":"B-lymphoid blast phase-chronic myeloid leukemia: current therapeutics","volume":"23","author":"Yohannan B","year":"2022","unstructured":"Yohannan B, George B. B-lymphoid blast phase-chronic myeloid leukemia: current therapeutics. Int J Mol Sci. 2022, 23:10.3390\/ijms231911836","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02320-9","article-title":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells","volume":"38","author":"Chatain N","year":"2024","unstructured":"Chatain N, Baumeister J, Szymanski de Toledo MA, et al.. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells. Leukemia. 2024, 38:1825-30. 10.1038\/s41375-024-02320-9","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus A","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, et al.. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023, 37:617-26. 10.1038\/s41375-023-01829-9","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6478","article-title":"A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib","volume":"10","author":"Tomassetti S","year":"2022","unstructured":"Tomassetti S, Lee J, Qing X. A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib. Clin Case Rep. 2022, 10:10.1002\/ccr3.6478","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452926-from-molecular-silence-to-lymphoid-blast-phase-diagnostic-and-therapeutic-challenges-in-a-young-female-patient-with-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T20:26:08Z","timestamp":1771446368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452926-from-molecular-silence-to-lymphoid-blast-phase-diagnostic-and-therapeutic-challenges-in-a-young-female-patient-with-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.103856","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}